©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Oncol. Aug 10, 2015; 6(4): 35-42
Published online Aug 10, 2015. doi: 10.5306/wjco.v6.i4.35
Published online Aug 10, 2015. doi: 10.5306/wjco.v6.i4.35
Concurrent chemoradiation for high-risk prostate cancer
Benjamin T Cooper, Nicholas J Sanfilippo, Department of Radiation Oncology, New York University School of Medicine, New York, NY 10016, United States
Author contributions: Cooper BT and Sanfilippo NJ wrote this paper.
Conflict-of-interest statement: The authors have no real or potential conflicts of interest.
Correspondence to: Nicholas Sanfilippo, MD, Department of Radiation Oncology, New York University School of Medicine, 160 East 34th Street, New York, NY 10016, United States. nicholas.sanfilippo@nyumc.org
Telephone: +1-212-7315003 Fax: +1-212-7315517
Received: March 26, 2015
Peer-review started: March 28, 2015
First decision: April 27, 2015
Revised: May 6, 2015
Accepted: July 7, 2015
Article in press: July 8, 2015
Published online: August 10, 2015
Processing time: 143 Days and 16.9 Hours
Peer-review started: March 28, 2015
First decision: April 27, 2015
Revised: May 6, 2015
Accepted: July 7, 2015
Article in press: July 8, 2015
Published online: August 10, 2015
Processing time: 143 Days and 16.9 Hours
Core Tip
Core tip: Over half of patients with high-risk prostate cancer will have a biochemical relapse within 5 years when treated primarily with radiotherapy as shown in multiple studies. One method that has been shown to improve local control, and in some disease sites overall survival, is the addition of chemotherapy to radiotherapy for definitive treatment. We review the safety and efficacy data of combined chemoradiation in patients with high risk adenocarcinoma of the prostate.